1 ESGE recommends in patients with acute upper gastrointestinal hemorrhage (UGIH) the
use of the Glasgow–Blatchford Score (GBS) for pre-endoscopy risk stratification. Patients …

Anticoagulation carries a tremendous therapeutic advantage in reducing morbidity and
mortality with venous thromboembolism and atrial fibrillation. For over six decades …

Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal
disorders is challenging because of the potential for interference with the absorption of …

Background: Although dabigatran has a favorable risk-benefit profile compared with vitamin
K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major …

Introduction: there is limited experience and understanding of massive nonvariceal
gastrointestinal bleeding during therapy with direct-acting oral anticoagulants. Objectives: to …

Новые пероральные антикоагулянты (НОАК) прямой ингибитор тромбина дабигатран,
селективные ингибиторы фактора Xaривароксабан и апиксабан все шире …

Objectives This study was aimed to reveal risk factors for delayed bleeding after endoscopic
resection (ER) of superficial non‐ampullary duodenal epithelial tumors (SNADETs) and at …

Stroke prevention with oral anticoagulants in patients with atrial fibrillation predisposes for
bleeding. As a result, in select patient groups anticoagulation is withheld because of a …

Gastrointestinal bleeding, responsible for 612,000 hospital days and $1.2 billion in
aggregate health care expenditures in 2009, 1 is a common clinical problem encountered by …

The use of any anticoagulant is associated with an increased risk of bleeding, and bleeding
complications can be life-threatening. Management of bleeding in individuals who are …